Friday, May 13, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Scientific statement from the American Heart Association on COVID-19 and cardiovascular complications in children and adolescents

by Medical Finance
in Coronavirus
Study: SARS-CoV-2 Infection and Associated Cardiovascular Manifestations and Complications in Children and Young Adults: A Scientific Statement From the American Heart Association. Image Credit: visivastudio/Shutterstock
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

A recent scientific statement published in Circulation reviewed the current knowledge on coronavirus disease 2019 (COVID-19).

Study: SARS-CoV-2 Infection and Associated Cardiovascular Manifestations and Complications in Children and Young Adults: A Scientific Statement From the American Heart Association. Image Credit: visivastudio/Shutterstock
Study: SARS-CoV-2 Infection and Associated Cardiovascular Manifestations and Complications in Children and Young Adults: A Scientific Statement From the American Heart Association. Image Credit: visivastudio/Shutterstock

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the coronavirus that causes COVID-19, which generally causes fever, cough, chills, hypoxia, and dyspnea. Besides, COVID-19 is implicated as a complex multi-organ disease affecting various extra-pulmonary organs. Pre-existing cardiovascular disorders increase the risk of COVID-19-related morbidity and mortality.

In the present statement, researchers elucidated the epidemiology, pathophysiology, clinical presentations, treatment, and outcomes of COVID-19. They also reviewed the health consequences in young adults and children with congenital or acquired heart disease.

Epidemiology, pathophysiology, and clinical presentation of COVID-19

SARS-CoV-2 infections have been recorded globally across all age groups, races, and ethnicities. Early in the pandemic, children and young adults were less frequently or severely affected by COVID-19 than older adults. Nevertheless, some young adults and children are at a higher risk of severe illness. Underlying medical conditions in children increase the odds of hospitalization, intensive care, and mortality.

SARS-CoV-2 attaches to the host angiotensin-converting enzyme-2 (ACE2) through its spike (S) protein, where the transmembrane protease, serine 2 (TMPRSS2) of the host cells cleaves and activates the S protein, facilitating entry cells. As with the cardiovascular involvement in COVID-19, several mechanisms have been proposed, including 1) direct SARS-CoV-2 invasion of cardiomyocytes that highly express ACE2 causing cellular damage, 2) injury of cardiomyocytes due to the overwhelming inflammatory response, and 3) ischemic myocardial injury due to hypoxia.

As ACE2 receptors increase on the cell surface with age, the lower levels of ACE2 might explain why children experience less severe disease. Clinically, COVID-19 results in the acute or hyperinflammatory phase. Around 8% – 19% of children and adolescents develop asymptomatic COVID-19, and symptomatic cases present cough and fever. Moreover, ageusia and anosmia are less frequently reported in children than adults. Cardiovascular manifestations are uncommon during acute COVID-19 in children. Although comorbid children are at a higher risk for symptomatic COVID-19 than healthy children, cardiovascular complications, severe illness, and mortality are uncommon.

Multisystem inflammatory syndrome in children (MIS-C)

Children with COVID-19 rarely develop MIS-C, a severe complication of the disease. A systematic review of more than 900 children revealed that MIS-C symptoms were fever, diarrhea, vomiting, abdominal pain, oral mucosal changes, non-purulent conjunctivitis, and rash. Nearly half the MIS-C cases have myocardial involvement, including myocarditis (in up to 19% of cases), coronary artery dilation (12% – 21%), decreased left ventricular function (28% – 55%), and pericardial effusion (23%). Fortunately, MIS-C resolves within one to four weeks of diagnosis with a mortality rate of 1.4% – 1.9%.

COVID-19 treatment and management

A health care professional may evaluate COVID-19 patients complaining of dyspnea, while those with severe disease or comorbidities may be managed in hospitals. Antivirals and immune modulators may be indicated for severe illness. Although no COVID-19-specific antiviral therapy exists, existing drugs such as antivirals, antimalarial, and antibacterial drugs have been repurposed.

Remdesivir is the only drug approved by the food and drug administration (FDA) for hospitalized patients aged 12 years or above. Using dexamethasone during severe disease has reduced the adult mortality rate. At the same time, it is indicated for children who need high-flow oxygen, invasive or non-invasive ventilation, or extracorporeal membrane oxygenation (ECMO). Dexamethasone is not recommended for children with mild or moderate disease. Treatment of patients with MIS-C mainly modulates the inflammatory state and supportive care.

Congenital heart disease, pulmonary hypertension, and organ transplantations

Reports regarding the severity of COVID-19 in children and adolescents with congenital heart disease are conflicting, with some suggesting a high risk of severe illness and others reporting variable risk. Low infection and mortality rates have been observed for children with congenital heart disease. However, an underlying syndrome such as trisomy 21 increases the risk of severe COVID-19.

One study found a similar mortality rate among children and adults with congenital heart disease. Pulmonary arterial hypertension (PAH) is associated with a high risk of severe COVID-19. However, some studies suggested a similar infection rate between pediatric patients with idiopathic PAH and general pediatric patients.

Studies on children with solid-organ transplants found no evidence of high risk. However, more research is needed to explicitly understand the risk of SARS-CoV-2 on the graft. Interestingly, tacrolimus indicated in immunosuppressive therapy demonstrated in vitro activity against the viral replication, suggesting that the continued use of the drug might be reasonable.

Conclusions

COVID-19 remains a relatively new disease, and the associated knowledge on disease prognosis, prevention, and treatment is still evolving. It is crucial to understand the mechanisms of MIS-C better and find an optimal and effective treatment. Furthermore, antiviral therapies should be evaluated in clinical trials, including in children. More research is required to delineate the associated risks of congenital heart disease. The impact of COVID-19 on the heart and the consequences of the post-COVID-19 syndrome or long COVID need to be elucidated in children and adolescents.  

Journal reference:

  • SARS-CoV-2 Infection and Associated Cardiovascular Manifestations and Complications in Children and Young Adults: A Scientific Statement From the American Heart Association. Jone, Pei-Ni, Anitha John, Matthew E. Oster, Kiona Allen, Adrianna H. Tremoulet, Elizabeth V. Saarel, Linda M. Lambert, Shelley D. Miyamoto, Sarah D. de Ferranti, and on behalf of the American Heart Association Leadership Committee and Congenital Cardiac Defects Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Hypertension, and Council on Peripheral Vascular Disease. Circulation. doi:  https://doi.org/10.1161/CIR.0000000000001064 https://www.ahajournals.org/doi/10.1161/CIR.0000000000001064
Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: Rapid emergence of SARS-CoV-2 Omicron variant is associated with an infection advantage over Delta in vaccinated persons. Image Credit: DOERS / Shutterstock.com

Escape from vaccine-induced immunity likely contributed to rapid rise of SARS-CoV-2 Omicron

by Medical Finance
May 12, 2022
0

In a recent study published on the medRxiv* preprint server, researchers investigate whether the severe acute respiratory syndrome coronavirus 2...

Study: mRNA-1273 Vaccine-elicited Neutralization of SARS-CoV-2 Omicron in Adolescents and Children. Image Credit: rafapress / Shutterstock.com

Children and adolescents respond as well or better than adults to mRNA-1273 COVID vaccination

by Medical Finance
May 12, 2022
0

A recent study published on the medRxiv* preprint server assesses the neutralization efficacy of the Moderna mRNA-1273 vaccine against the...

Study: Comparative immunogenicity of heterologous versus homologous 3rd SARS-CoV-2 vaccine doses in kidney transplant recipients. Image Credit: Wetzkaz Graphics / Shutterstock.com

Study shows homologous COVID boosters better than heterologous in most kidney transplant recipients

by Medical Finance
May 12, 2022
0

In a recent study posted to the medRxiv* preprint server, researchers screen kidney transplant recipients to evaluate their serological responses following...

Study: Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants. Image Credit: GEMINI PRO STUDIO / Shutterstock.com

Immunity based upon “mild” Omicron infection is weak for Omicron reinfection

by Medical Finance
May 12, 2022
0

In a recent study published on the medRxiv* preprint server, an interdisciplinary team of researchers from the United States evaluate...

Study: Vaccine hesitancy and access to psoriasis care in the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey. Image Credit: Fuss Sergey/Shutterstock.com

Study explores factors associated with COVID-19 vaccine hesitancy in individuals with psoriasis

by Medical Finance
May 12, 2022
0

About 40% of people living with psoriasis have had delays to psoriasis treatment and care from the COVID-19 pandemic, according...

Severe radiological changes after infection with SARS-CoV-2. (A) Compiled radiographic scores. Bar graph depicts the mean with standard deviation and individuals, ordinary one-way ANOVA with Tukey’s multiple comparisons test. Radiographs demonstrate multifocal pulmonary infiltrates, most severe in the left and right caudal lung lobes depicted in the (B) dorsoventral radiograph (C) left lateral and (D) right lateral radiograph on the evening of 2 days post-inoculation (DPI). Arrows depict grade 4 pulmonary disease in the left and right caudal lung lobes with grade 3 pulmonary disease in the right middle lung lobe and cranial subsegment of the left cranial lung lobe.

Research shows minks mimic severe COVID-19 symptoms, including ARDS

by Medical Finance
May 12, 2022
0

Minks may be a suitable animal model for testing severe COVID-19 infections, finds a recent bioRxiv* preprint study. While mice...

Next Post
Omicron variant found to be much less sensitive to neutralizing antibodies than Delta

SARS-CoV-2 virus may be shed for much longer periods by some infected patients, study shows

AI-driven solution predicts RNA and DNA binding sites to accelerate rational drug discovery

Structural proteomics approaches can help in the treatment of neurodegenerative diseases

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Two cell embryo Mitosis under microscope 3D illustration Illustration Andrii Vodolazhskyi M1 4bb73c51d46c449285a21e8af28684d6 620x480
    COVID-19 mortality among elderly may be due to genetically predetermined limit on the immune system
  • Study: Nasopharyngeal Microbiota Profiling of Pregnant Women With Sars-Cov-2 Infection. Image Credit: NIAID
    Study shows SARS-CoV-2 infection can change nasopharyngeal microbiota composition in pregnancy
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply